{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:27:58Z","timestamp":1784348878664,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Ectopic adrenocorticotropic hormone secretion (EAS) is responsible for approximately 10%\u201318% of Cushing\u2019s syndrome cases. Thymic neuroendocrine tumors (NETs) comprise 5%\u201316% of EAS; therefore, they are very rare and the data about this particular tumors is scarce. We present a case of a 34-year-old woman with a rapid onset of severe hypercortisolism in April 2016. After initial treatment with a steroid inhibitor (ketoconazole) and diagnostics including <jats:sup>68<\/jats:sup>Ga DOTA-TATE PET\/CT, it was shown to be caused by a small thymic NET. After a successful surgery and the resolution of all symptoms, there was a recurrence after 5 years of observation caused by a metastasis to the breast, shown in the <jats:sup>68<\/jats:sup>Ga DOTA-TATE PET\/CT result and confirmed with a breast biopsy. Treatment with a steroid inhibitor (metyrapone) and tumor resection were again curative. The last disease relapse appeared 7 years after the initial treatment, with severe hypercortisolism treated with osilodrostat. There was a local recurrence in the mediastinum, and a thoracoscopic surgery was performed with good clinical and biochemical effect. The patient remains under careful follow-up. Our case stays in accordance with recent literature data, showing that patients with thymic NETs are younger than previously considered and that the severity of hypercortisolism does not correlate with the tumor size. The symptoms of EAS associated with thymic NET may develop rapidly and may be severe as in our case. Nuclear medicine improves the effectiveness of the tumor search, which is crucial in successful EAS therapy. Our case also underlines the need for lifelong monitoring of patients with thymic NETs and EAS.<\/jats:p>","DOI":"10.3389\/fonc.2025.1492187","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:01:05Z","timestamp":1740484865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Thymic neuroendocrine tumor with metastasis to the breast causing ectopic Cushing\u2019s syndrome"],"prefix":"10.3389","volume":"15","author":[{"given":"Aleksandra","family":"Zdrojowy-We\u0142na","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Bolanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Syrycka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Jawiarczyk-Przyby\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kuliczkowska-P\u0142aksej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1530\/EJE-19-0877","article-title":"Management of endocrine disease: Cushing\u2019s syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S44336","article-title":"Cushing`s syndrome: epidemiology and developments in disease management","volume":"7","author":"Feelders","year":"2015","journal-title":"Clin Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.02.005","article-title":"Mortality in patients with endogenous cushing\u2019s syndrome","volume":"47","author":"Javanmard","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v117.19","article-title":"Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience","volume":"117","author":"Ejaz","year":"2011","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-008-1274-5","article-title":"Imaging in covert ectopic ACTH secretion: a CT pictorial review","volume":"19","author":"Sookur","year":"2009","journal-title":"Eur Radiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4158\/EP15662.OR","article-title":"Pituitary MRI findings in patients with pituitary and ectopic ACTH-dependent cushing syndrome: does A 6- mm pituitary tumor size cut-off value exclude ectopic acth syndrome","volume":"21","author":"Yogi-Morren","year":"2015","journal-title":"Endocr Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2527","article-title":"Cushing\u2019s syndrome due to ectopic corticotropin secretion: twenty years\u2019 Experience at the national institutes of health","volume":"90","author":"Ilias","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2015-1589","article-title":"Conventional and nuclear medicine imaging in ectopic cushing\u2019s syndrome: A systematic review","volume":"100","author":"Isidori","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05370-8","article-title":"Head-to-head comparison of 68Ga- DOTATATE PET\/CT and 18F-FDG PET\/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study","volume":"48","author":"Liu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09660-2","article-title":"Ectopic Cushing\u2019s syndrome due to thymic neuroendocrine tumours: a systematic review","volume":"22","author":"Guerrero-P\u00e9rez","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3355","article-title":"Neuroendocrine ACTH-producing tumor of the thymus\u2014Experience with 12 patients over 25 years","volume":"97","author":"Neary","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1399930\/full","article-title":"Case report: A challenging case of severe Cushing\u2019s syndrome in the course of metastatic thymic neuroendocrine carcinoma with a synchronous adrenal tumor","author":"Dzialach","year":"2024","journal-title":"Front Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3233\/BD-130354","article-title":"Breast metastases from an adrenocorticotropic hormone secreting thymic neuro-endocrine tumor","volume":"34","author":"Gaur","year":"2013","journal-title":"Breast Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-013-2037-2","article-title":"Metastases from neuroendocrine tumors to the breast are more common than previously thought. A diagnostic pitfall","volume":"37","author":"Crona","year":"2013","journal-title":"World J Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.790975","article-title":"Case report: an unusual case of ectopic ACTH syndrome caused by mediastinal paraganglioma","volume":"12","author":"Li","year":"2021","journal-title":"Front Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1155","article-title":"Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series","volume":"90","author":"Ferolla","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (Carcinoid tumor) of the thymus","volume":"114","author":"Moran","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4158\/EP13171.OR","article-title":"Ectopic acth- secreting syndrome: A single-center experience","volume":"19","author":"Kakade","year":"2013","journal-title":"Endocr Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.08.18","article-title":"Neuroendocrine tumors of the thymus: the oncologist point of view","volume":"9","author":"Girard","year":"2017","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000526811","article-title":"Efficacy and safety of lanreotide autogel and temozolomide combination therapy in progressive thoracic neuroendocrine tumors (Carcinoid): results from the phase 2 ATLANT study","volume":"113","author":"Ferolla","year":"2023","journal-title":"Neuroendocrinology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","article-title":"Treatment of Cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples","volume":"25","author":"Fleseriu","year":"2022","journal-title":"Pituitary"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1492187\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:01:09Z","timestamp":1740484869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1492187\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1492187"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1492187","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"article-number":"1492187"}}